Climb Bio, Inc.
CLYM
$7.03
-$0.09-1.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.91% | -48.72% | 58.30% | -146.92% | 5.39% |
| Total Depreciation and Amortization | 3.45% | -23.68% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -83.35% | 614.46% | -65.32% | 15.78% | -53.92% |
| Change in Net Operating Assets | 145.44% | 7.41% | -176.60% | 135.11% | 227.25% |
| Cash from Operations | -28.80% | -8.89% | 27.77% | -179.55% | 26.92% |
| Capital Expenditure | 100.00% | -41.56% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.17% | 216.04% | 111.38% | 19.96% | 25.60% |
| Cash from Investing | 67.35% | 218.85% | 111.20% | 19.96% | 25.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -87.19% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -98.19% |
| Foreign Exchange rate Adjustments | -- | -- | 200.00% | 57.89% | -152.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 216.63% | 149.24% | 89.11% | 1.25% | 23.41% |